Cargando…
m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer
Methylation has a close relationship with immune reactions, metastasis, and cancer cell growth. Additionally, RNA methylation-related proteins have emerged as potential cancer therapeutic targets. The connection between the tumor microenvironment (TME) and methylation-related genes (MRGs) remains un...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596993/ https://www.ncbi.nlm.nih.gov/pubmed/36313300 http://dx.doi.org/10.3389/fphar.2022.1030766 |
_version_ | 1784815994075611136 |
---|---|
author | Ye, Xin Wang, Ruyi Yu, Xiaoqian Wang, Zili Hu, Haifeng Zhang, Hanchao |
author_facet | Ye, Xin Wang, Ruyi Yu, Xiaoqian Wang, Zili Hu, Haifeng Zhang, Hanchao |
author_sort | Ye, Xin |
collection | PubMed |
description | Methylation has a close relationship with immune reactions, metastasis, and cancer cell growth. Additionally, RNA methylation-related proteins have emerged as potential cancer therapeutic targets. The connection between the tumor microenvironment (TME) and methylation-related genes (MRGs) remains unclear. We explored the expression patterns of the MRGs in the genome and transcriptional fields of 796 prostate cancer (PCa) samples using two separate data sets. We identified a relationship between patient clinicopathological characteristics, prognosis, TME cell infiltrating qualities, and different MRG changes, as well as the identification of two distinct molecular groupings. Then, we formed an MRGs model to predict overall survival (OS), and we tested the accuracy of the model in patients with PCa. In addition, we developed a very accurate nomogram to improve the MRG model’s clinical applicability. The low-risk group had fewer tumor mutational burden (TMB), greater tumor immune dysfunction and exclusion (TIDE) ratings, fewer mutant genes, and better OS prospects. We discuss how MGRs may affect the prognosis, clinically important traits, TME, and immunotherapy responsiveness in PCa. In order to get a better understanding of MRGs in PCa, we could further explore the prognosis and create more effective immunotherapy regimens to open new avenues. |
format | Online Article Text |
id | pubmed-9596993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95969932022-10-27 m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer Ye, Xin Wang, Ruyi Yu, Xiaoqian Wang, Zili Hu, Haifeng Zhang, Hanchao Front Pharmacol Pharmacology Methylation has a close relationship with immune reactions, metastasis, and cancer cell growth. Additionally, RNA methylation-related proteins have emerged as potential cancer therapeutic targets. The connection between the tumor microenvironment (TME) and methylation-related genes (MRGs) remains unclear. We explored the expression patterns of the MRGs in the genome and transcriptional fields of 796 prostate cancer (PCa) samples using two separate data sets. We identified a relationship between patient clinicopathological characteristics, prognosis, TME cell infiltrating qualities, and different MRG changes, as well as the identification of two distinct molecular groupings. Then, we formed an MRGs model to predict overall survival (OS), and we tested the accuracy of the model in patients with PCa. In addition, we developed a very accurate nomogram to improve the MRG model’s clinical applicability. The low-risk group had fewer tumor mutational burden (TMB), greater tumor immune dysfunction and exclusion (TIDE) ratings, fewer mutant genes, and better OS prospects. We discuss how MGRs may affect the prognosis, clinically important traits, TME, and immunotherapy responsiveness in PCa. In order to get a better understanding of MRGs in PCa, we could further explore the prognosis and create more effective immunotherapy regimens to open new avenues. Frontiers Media S.A. 2022-10-12 /pmc/articles/PMC9596993/ /pubmed/36313300 http://dx.doi.org/10.3389/fphar.2022.1030766 Text en Copyright © 2022 Ye, Wang, Yu, Wang, Hu and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Ye, Xin Wang, Ruyi Yu, Xiaoqian Wang, Zili Hu, Haifeng Zhang, Hanchao m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer |
title | m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer |
title_full | m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer |
title_fullStr | m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer |
title_full_unstemmed | m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer |
title_short | m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer |
title_sort | m(6)a/ m(1)a /m(5)c/m(7)g-related methylation modification patterns and immune characterization in prostate cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596993/ https://www.ncbi.nlm.nih.gov/pubmed/36313300 http://dx.doi.org/10.3389/fphar.2022.1030766 |
work_keys_str_mv | AT yexin m6am1am5cm7grelatedmethylationmodificationpatternsandimmunecharacterizationinprostatecancer AT wangruyi m6am1am5cm7grelatedmethylationmodificationpatternsandimmunecharacterizationinprostatecancer AT yuxiaoqian m6am1am5cm7grelatedmethylationmodificationpatternsandimmunecharacterizationinprostatecancer AT wangzili m6am1am5cm7grelatedmethylationmodificationpatternsandimmunecharacterizationinprostatecancer AT huhaifeng m6am1am5cm7grelatedmethylationmodificationpatternsandimmunecharacterizationinprostatecancer AT zhanghanchao m6am1am5cm7grelatedmethylationmodificationpatternsandimmunecharacterizationinprostatecancer |